HOX Therapeutics is developing new treatments for prostate cancer including a new class of drugs based on the inhibition of HOX transcription factors, development genes which are overexpressed in cancer. In a parallel programme HOX is working on novel inhibitors of the androgen receptors in those patients insensitive to current drugs for castration resistant prostate cancer.